<DOC>
	<DOCNO>NCT02111096</DOCNO>
	<brief_summary>The intent study assess safety LY2409021 participant Type 2 diabetes mellitus take metformin sulfonylurea prescribe personal physician . The study treatment expect last 12 month ( 52 week ) .</brief_summary>
	<brief_title>A Study LY2409021 Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Have treat stable dose metformin least 3 month treat optimally effective stable dose sulfonylurea least 6 month prior screen . HbA1c value 7.0 % 10.0 % , inclusive . Body mass index ( BMI ) 20 45 kilograms/square meter ( kg/m^2 ) , inclusive . Known type 1 diabetes mellitus . More 1 episode severe hypoglycemia within 6 month prior screen . Two emergency room visit hospitalization due poor glucose control 6 month prior screen . Severe gastrointestinal disease may significantly impact gastric empty motility undergone gastric bypass gastric banding surgery . Previous history active diagnosis pancreatitis . Positive hepatitis B surface antigen hepatitis C antibody . Clinical sign symptom liver disease , hepatic aminotransferase ( aminotransferase alanine aminotransferase ) great 2.0Ã— upper limit normal ( ULN ) elevate alkaline phosphatase ( great ULN ) unrelated bone metabolic disease . Elevated total bilirubin level ( great ULN ) , clinically suspicious signs/symptoms cirrhosis history cirrhosis . Current diagnosis , personal history neuroendocrine tumor , family history type multiple endocrine neoplasia ( MEN ) , Von HippelLindau . Contraindications magnetic resonance imaging .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>